O'Shaughnessy Asset Management’s Nektar Therapeutics NKTR Stock Holding History

O'Shaughnessy Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2	Closed	-$1K	–	2031
2021 Q3	$1K	Hold	2	–	–	﹤0.01%	2608
2021 Q2	$1K	Sell	2 -1	-33%	-$277	﹤0.01%	2461
2021 Q1	$1K	Hold	3	–	–	﹤0.01%	2229
2020 Q4	$1K	Hold	3	–	–	﹤0.01%	1969
2020 Q3	$1K	Sell	3 -3	-50%	-$944	﹤0.01%	1763
2020 Q2	$2K	Buy	+6	New	+$1.87K	﹤0.01%	1508
2020 Q1	–	Sell	-1	Closed	–	–	1625
2019 Q4	$0	Buy	+1	New	+$290	﹤0.01%	1875

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

O'Shaughnessy Asset Management's NKTR Position: Q4 2021 in Review

O'Shaughnessy Asset Management sold out of Nektar Therapeutics (NKTR) in Q4 2021, closing a stake of 2 shares — an estimated $1K sold.

O'Shaughnessy Asset Management first reported a position in NKTR in Q4 2019 and held it in 7 quarters. The position peaked at $2K in Q2 2020. 240 funds tracked by Wall St. Rank hold NKTR as of Q4 2021.

O'Shaughnessy Asset Management reported no remaining Nektar Therapeutics position as of Q4 2021 after selling out during the quarter.
O'Shaughnessy Asset Management sold 2 Nektar Therapeutics shares in Q4 2021, an estimated $1K.
O'Shaughnessy Asset Management first reported a position in Nektar Therapeutics in Q4 2019 and held it in 7 quarters.
O'Shaughnessy Asset Management's Nektar Therapeutics position peaked at $2K in Q2 2020.
240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2021.

Based on O'Shaughnessy Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.